Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Catrin Treharne"'
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 11 (2024)
In this latest update, we explore the recent announcement by Canada’s Drug Agency (CDA-AMC, formerly CADTH) on their pilot to include the societal perspective in the evaluation of certain new medicines; a recent Office of Health Economics (OHE) r
Externí odkaz:
https://doaj.org/article/6252f13a678047849743b433c45bf759
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 6, Iss 13 (2024)
In this latest update, we look at recent developments in market access including the pricing agreement of Libmeldy by the Beneluxa Initiative, the financial impact of managed entry agreements in Italy and the restructuring of Agenzia Italiana del Far
Externí odkaz:
https://doaj.org/article/d3c9f59e8747475a96b2efec8b3342b7
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 3 (2024)
In this latest update, we explore some of the key updates in market access over recent months including the UK’s voluntary scheme for branded medicines pricing, access and growth (VPAG), the first drugs funded by the Innovative Medicines Fund in th
Externí odkaz:
https://doaj.org/article/afc97ac51a8b48b398a9a27ebcce3c5c
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 12 (2023)
In this latest update, we explore the Inflation Reduction Act (IRA) enacted by the US Congress in August 2022, with the Centers for Medicare and Medicaid Services (CMS) recently releasing the list of the first ten drugs it will negotiate prices on.
Externí odkaz:
https://doaj.org/article/9e881e7c2d8848cf962835d96bec5d7b
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 10 (2023)
In this new series reviewing recent developments inmarket access, we highlight publications investigating health technology assessment (HTA) guidance, review processes and outcomes across the world and discuss how forthcoming changes in the HTA and
Externí odkaz:
https://doaj.org/article/10f45dd6cefd4f2985af78e01fbc3828
Publikováno v:
Journal of Comparative Effectiveness Research (2023)
Externí odkaz:
https://doaj.org/article/8d9d4e6b711a4589810a62d2f752d412
Publikováno v:
International journal of chronic obstructive pulmonary disease. 17
Enrico de Nigris,1 Catrin Treharne,2 Nick Brighton,2 Ulf Holmgren,3 Andrew Walker,4 John Haughney5 1Formerly of Global Product and Portfolio Strategy, AstraZeneca, Cambridge, UK; 2Formerly of Health Economic Modelling, Regulatory and Access, Parexel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad4bae01d626840ad31f3c99811e3f1
https://pubmed.ncbi.nlm.nih.gov/36444374
https://pubmed.ncbi.nlm.nih.gov/36444374
Peritoneal Dialysis and In-Centre Haemodialysis: A Cost-Utility Analysis from a UK Payer Perspective
Publikováno v:
Applied Health Economics and Health Policy
Background With limited healthcare resources available, cost-effective provision of dialysis to patients with end-stage renal disease (ESRD) is important. Objectives To assess the cost-effectiveness of varying levels of peritoneal dialysis (PD) use v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e948bfe04edfa4e723f2fec282980a5e
http://europepmc.org/articles/PMC4110409
http://europepmc.org/articles/PMC4110409
Publikováno v:
BMC Nephrology
Background Evidence suggests that high dose haemodialysis (HD) may be associated with better health outcomes and even cost savings (if conducted at home) versus conventional in-centre HD (ICHD). Home-based regimens such as peritoneal dialysis (PD) ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a8f7f7f06812e104decf6c31cf88d46
https://doi.org/10.1186/1471-2369-15-161
https://doi.org/10.1186/1471-2369-15-161
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 18(1)
Objective To investigate the cost-effectiveness of high-dose hemodialysis (HD) versus conventional in-center HD (ICHD), over a lifetime time horizon from the UK payer's perspective. Methods We used a Markov modeling approach to compare high-dose HD (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e3beebdce895786fd19a5b4060dc377
https://pubmed.ncbi.nlm.nih.gov/25595230
https://pubmed.ncbi.nlm.nih.gov/25595230